These observations were confirmed in a study of the ADNI cohort, where, longitudinally, there was an elevation of CSF YKL-40 levels in all the groups over the mean follow-up time of 4 years, although the change in the biomarker was significant only in mild cognitive-impaired Aβ-positive patients [190]. Here, CHI3L1 is linked to Cognitive impairment.